DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea

Recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: Ozanimod

First Posted Date: 2023-10-10

Last Posted Date: 2024-08-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 3000

Registration Number: NCT06073873

Locations: 🇰🇷
Bristol-Myers Squibb YH, Seoul, Korea, Republic of

A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Oral azacitidine

First Posted Date: 2023-10-10

Last Posted Date: 2024-11-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 154

Registration Number: NCT06073769

Locations: 🇰🇷
Local Institution - 0001, Seoul, Korea, Republic of
🇰🇷
Novotech Laboratory Korea Co., Ltd., Seoul, Korea, Republic of

A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis

Recruiting

Conditions: Primary Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis

Interventions: Drug: Fedratinib

First Posted Date: 2023-10-10

Last Posted Date: 2024-11-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 137

Registration Number: NCT06073847

Locations: 🇰🇷
Local Institution - 0001, Seoul, Korea, Republic of
🇰🇷
Novotech Laboratory Korea Co., Ltd., Seoul, Korea, Republic of
🇰🇷
Bristol-Myers Squibb YH, Seoul, Korea, Republic of

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

Phase 1

Recruiting

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: BMS-986460

First Posted Date: 2023-10-05

Last Posted Date: 2024-08-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 90

Registration Number: NCT06067841

Locations: 🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States
🇺🇸
Local Institution - 0006, San Antonio, Texas, United States

and more 5 locations

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

Phase 3

Recruiting

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Luspatercept

First Posted Date: 2023-09-21

Last Posted Date: 2025-04-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 100

Registration Number: NCT06045689

Locations: 🇵🇷
Auxilio Mutuo Cancer Center, San Juan, Puerto Rico
🇪🇸
ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain
🇪🇸
Hospital Universitario Vall d'Hebron - PPDS, Barcelona, Spain

and more 61 locations

A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

Phase 4

Terminated

Conditions: Palmoplantar Psoriasis
Genital Psoriasis

Interventions: Drug: Deucravacitinib
Drug: Placebo

First Posted Date: 2023-09-21

Last Posted Date: 2025-05-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 131

Registration Number: NCT06042920

Locations: 🇨🇦
Local Institution - 0065, Montreal, Quebec, Canada
🇨🇦
Local Institution - 0054, Montreal, Quebec, Canada
🇨🇦
Local Institution - 0059, Québec, Quebec, Canada

and more 28 locations

A Study to Evaluate the Effect of Food on the Drug Levels of BMS-986196 in Healthy Adult Participants

Phase 1

Withdrawn

Conditions: Healthy Adult Volunteers

Interventions: Drug: BMS-986196

First Posted Date: 2023-09-13

Last Posted Date: 2023-09-21

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT06034899

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Phase 1

Recruiting

Conditions: Relapsed or Refractory T-cell Lymphomas

Interventions: Drug: BMS-986369

First Posted Date: 2023-09-13

Last Posted Date: 2025-05-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 85

Registration Number: NCT06035497

Locations: 🇯🇵
Anjo Kosei Hospital, Anjo-shi, Aichi, Japan
🇯🇵
Nagoya City University Hospital, Nagoya, Aichi, Japan
🇯🇵
Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan

and more 37 locations

A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Danicamtiv

First Posted Date: 2023-09-07

Last Posted Date: 2023-11-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 21

Registration Number: NCT06027437

Locations: 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States

A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Phase 1

Terminated

Conditions: Advanced Solid Tumors

Interventions: Drug: BMS-986466
Drug: Adagrasib
Drug: Cetuximab

First Posted Date: 2023-09-06

Last Posted Date: 2024-06-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 5

Registration Number: NCT06024174

Locations: 🇺🇸
Local Institution - 0025, Hackensack, New Jersey, United States
🇺🇸
Local Institution - 0047, Los Angeles, California, United States
🇦🇺
Local Institution - 0053, Westmead, New South Wales, Australia

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy